Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval

Popul Health Manag. 2021 Dec;24(6):638-639. doi: 10.1089/pop.2021.0189. Epub 2021 Sep 13.

Authors

Mark Angelo¹, Lawrence Ward²

Affiliations

¹ Department of Family Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
² Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

PMID: 34516238
DOI: 10.1089/pop.2021.0189

No abstract available

Keywords: Aduhelm; Alzheimer's disease; Medicare; aducanumab; amyloid plaque; dementia.

Publication types

Editorial

MeSH terms

Alzheimer Disease*
Antibodies, Monoclonal, Humanized*
Drug Approval*
Humans
Treatment Failure
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
aducanumab